GlassScriptPhysician profile
Avia J Facey
NPI 1205504420
$2,609.51
in general payments reported to CMS, 2019-2025
22 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $956 · 2023: $849 · 2024: $355 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310 · Education: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.17 |
| Education | $343.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $432.97 | 2022-2025 | Tagrisso, Calquence |
| Daiichi Sankyo INC. | $430.00 | 2022-2025 | Injectafer, Vanflyta, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $262.74 | 2022-2023 | Opdivo |
| Amgen INC. | $255.08 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Lilly USA, LLC | $240.31 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $172.94 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $138.22 | 2022-2025 | Fruzaqla, Ninlaro |
| Puma Biotechnology, INC. | $104.00 | 2023-2025 | |
| Gilead Sciences, INC. | $100.82 | 2023-2025 | Trodelvy |
| Astellas Pharma US INC | $99.00 | 2022 | |
| Stemline Therapeutics INC. | $68.75 | 2024-2025 | Orserdu |
| Kyowa Kirin, INC. | $67.33 | 2022-2023 | Poteligeo |
| Recordati_rare_diseases_inc. | $34.20 | 2025 | Sylvant |
| Genzyme Corporation | $33.34 | 2022-2023 | |
| Emd Serono, INC. | $29.88 | 2023 | Bavencio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $27.08 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.96 | 2022 | |
| Coherus Oncology, INC. | $22.36 | 2024 | |
| Eisai INC. | $21.79 | 2024 | |
| Pharmaessentia USA Corporation | $17.31 | 2025 | Besremi |
| Organon LLC | $14.24 | 2022 | |
| Seagen INC. | $14.19 | 2023 | Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avia Facey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.